Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group.
Rigolin GM, Cavazzini F, Piciocchi A, Arena V, Visentin A, Reda G, Zamprogna G, Cibien F, Vitagliano O, Coscia M, Farina L, Gaidano G, Murru R, Varettoni M, Paolini R, Sportoletti P, Pietrasanta D, Molinari AL, Quaglia FM, Laurenti L, Marasca R, Marchetti M, Mauro FR, Crea E, Vignetti M, Gentile M, Montillo M, Foà R, Cuneo A; GIMEMA Group. Rigolin GM, et al. Among authors: zamprogna g. Hematol Oncol. 2021 Aug;39(3):326-335. doi: 10.1002/hon.2861. Epub 2021 Mar 26. Hematol Oncol. 2021. PMID: 33739461 Free PMC article. Clinical Trial.
Ibrutinib for the treatment of chronic lymphocytic leukemia.
Deodato M, Frustaci AM, Zamprogna G, Cairoli R, Montillo M, Tedeschi A. Deodato M, et al. Among authors: zamprogna g. Expert Rev Hematol. 2019 May;12(5):273-284. doi: 10.1080/17474086.2019.1597703. Epub 2019 Apr 11. Expert Rev Hematol. 2019. PMID: 30916599 Review.
Duvelisib for the treatment of chronic lymphocytic leukemia.
Frustaci AM, Tedeschi A, Deodato M, Zamprogna G, Cairoli R, Montillo M. Frustaci AM, et al. Among authors: zamprogna g. Expert Opin Pharmacother. 2020 Aug;21(11):1299-1309. doi: 10.1080/14656566.2020.1751123. Epub 2020 Apr 15. Expert Opin Pharmacother. 2020. PMID: 32292084 Review.
Reply to "CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report" Analysis of six hematological centers in Lombardy : On behalf of CLL commission of Lombardy Hematology Network (REL).
Reda G, Noto A, Cassin R, Zamprogna G, Borella C, Scarfò L, Farina L, Molteni A, Ghia P, Tedeschi A, Montillo M; Rete Ematologica Lombarda (REL) Clinical Network. Reda G, et al. Among authors: zamprogna g. Leukemia. 2020 Sep;34(9):2531-2532. doi: 10.1038/s41375-020-0966-y. Epub 2020 Aug 4. Leukemia. 2020. PMID: 32753689 Free PMC article. No abstract available.
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
Vitale C, Salvetti C, Griggio V, Porrazzo M, Schiattone L, Zamprogna G, Visentin A, Vassallo F, Cassin R, Rigolin GM, Murru R, Laurenti L, Rivela P, Marchetti M, Pennese E, Gentile M, Boccellato E, Perutelli F, Montalbano MC, De Paoli L, Reda G, Orsucci L, Trentin L, Cuneo A, Tedeschi A, Scarfò L, Gaidano G, Mauro FR, Foà R, Boccadoro M, Coscia M. Vitale C, et al. Among authors: zamprogna g. Blood. 2021 Jun 24;137(25):3507-3517. doi: 10.1182/blood.2020008201. Blood. 2021. PMID: 33651883 Free article. Clinical Trial.
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
Tedeschi A, Frustaci AM, Mauro FR, Chiarenza A, Coscia M, Ciolli S, Reda G, Laurenti L, Varettoni M, Murru R, Baratè C, Sportoletti P, Greco A, Borella C, Rossi V, Deodato M, Biagi A, Zamprogna G, Pelle AC, Lapietra G, Vitale C, Morelli F, Cassin R, Fresa A, Cavalloni C, Postorino M, Ielo C, Cairoli R, Di Raimondo F, Montillo M, Del Poeta G. Tedeschi A, et al. Among authors: zamprogna g. Blood Adv. 2021 Dec 28;5(24):5490-5500. doi: 10.1182/bloodadvances.2021004824. Blood Adv. 2021. PMID: 34525181 Free PMC article.
18 results